EMMA (Emmaus Life Sciences) Beneish M-Score: -4.29 (As of Jun. 26, 2026)

What is Emmaus Life Sciences Beneish M-Score?

Emmaus Life Sciences EMMA -16.67% Beneish M-Score is -4.29 as of Jun. 26, 2026. The stock has 6 warning signs investors should review. Among 831 Biotechnology companies, Emmaus Life Sciences ranks better than 90.85% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.29 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Emmaus Life Sciences's Beneish M-Score or its related term are showing as below:

EMMA' s Beneish M-Score Range Over the Past 10 Years
Min: -32.93 Med: -2.71 Max: 16.06
Current: -4.29

During the past 13 years, the highest Beneish M-Score of Emmaus Life Sciences was 16.06. The lowest was -32.93. And the median was -2.71.

Emmaus Life Sciences Beneish M-Score Related Terms

Emmaus Life Sciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Beneish M-Score Chart

Emmaus Life Sciences Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

1.17

-3.93

5.13

-4.15

-3.91

Emmaus Life Sciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															-3.40	-3.77	-4.25	-3.91	-4.29

EMMA vs CERO, AGTX, WINT: Beneish M-Score Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Beneish M-Score falls into.

Save Embed

Emmaus Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Emmaus Life Sciences for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.3674

0.528 * 0.9956

0.404 * 0.9233

0.892 * 0.7267

0.115 * 0.2717

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.987

4.679 * -0.360131

0.327 * 1.3164

-4.29

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was $2.05 Mil.
Revenue was 1.982 + 3.852 + 3.378 + 2.817 = $12.03 Mil.
Gross Profit was 1.814 + 3.617 + 3.131 + 2.667 = $11.23 Mil.
Total Current Assets was $6.00 Mil.
Total Assets was $18.70 Mil.
Property, Plant and Equipment(Net PPE) was $0.83 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.05 Mil.
Selling, General, & Admin. Expense(SGA) was $10.66 Mil.
Total Current Liabilities was $70.54 Mil.
Long-Term Debt & Capital Lease Obligation was $3.60 Mil.
Net Income was -3.335 + -1.951 + -2.076 + -1.135 = $-8.50 Mil.
Non Operating Income was -0.443 + -0.617 + -0.326 + 0.256 = $-1.13 Mil.
Cash Flow from Operations was -0.344 + 2.209 + 0.409 + -2.908 = $-0.63 Mil.

Total Receivables was $2.06 Mil.
Revenue was 2.406 + 3.292 + 5.478 + 5.377 = $16.55 Mil.
Gross Profit was 2.181 + 2.983 + 5.084 + 5.136 = $15.38 Mil.
Total Current Assets was $5.65 Mil.
Total Assets was $22.48 Mil.
Property, Plant and Equipment(Net PPE) was $1.37 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.02 Mil.
Selling, General, & Admin. Expense(SGA) was $14.87 Mil.
Total Current Liabilities was $64.92 Mil.
Long-Term Debt & Capital Lease Obligation was $2.80 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(2.048 / 12.029)	/	(2.061 / 16.553)
	=	0.170255	/	0.124509
	=	1.3674

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(15.384 / 16.553)	/	(11.229 / 12.029)
	=	0.929378	/	0.933494
	=	0.9956

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (5.995 + 0.834) / 18.696)	/	(1 - (5.653 + 1.372) / 22.478)
	=	0.634735	/	0.687472
	=	0.9233

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	12.029	/	16.553
	=	0.7267

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.021 / (0.021 + 1.372))	/	(0.049 / (0.049 + 0.834))
	=	0.015075	/	0.055493
	=	0.2717

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(10.664 / 12.029)	/	(14.868 / 16.553)
	=	0.886524	/	0.898206
	=	0.987

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((3.601 + 70.537) / 18.696)	/	((2.795 + 64.915) / 22.478)
	=	3.965447	/	3.012279
	=	1.3164

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-8.497 - -1.13	-	-0.634)	/	18.696
	=	-0.360131

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Emmaus Life Sciences has a M-score of -4.29 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -4.29 mean?

Emmaus Life Sciences (EMMA) has a Beneish M-Score of -4.29 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #76 out of 831 companies in the Biotechnology industry, placing it in the top 9.1%.

Is Emmaus Life Sciences' Beneish M-Score too high?

Emmaus Life Sciences' current Beneish M-Score is -4.29. Based on the distribution chart, Emmaus Life Sciences ranks #76 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.

How does Emmaus Life Sciences' Beneish M-Score compare to CERO and AGTX?

According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #76 out of 831 companies for Beneish M-Score. This places Emmaus Life Sciences in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Beneish M-Score is -4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Emmaus Life Sciences stock overvalued right now?

Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Beneish M-Score is -4.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Beneish M-Score is -4.29 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Industry Healthcare Biotechnology

Comparable Companies CERO AGTX WINT RMTG EVFM LIPO PTIX ATXI CYTOF CNBX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503

Website https://www.emmausmedical.com

Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.